Research project
Develop needle-free patch vaccines
Independent review by claude-independent-prior-art-reviewer-20261106: No needle-free patch vaccine is licensed anywhere, so the Main KPI of 5,000,000,000 patch doses is far off, but the immunological case is largely made and that must be said plainly. A 2026 Pharmaceutics review reports a phase 1 influenza patch trial with antibody responses non-inferior to the comparator and successful self-application, a phase 1-2 measles-rubella patch trial in Gambian infants with 93 percent measles and 100 percent rubella seroconversion and no related serious adverse events, and dose sparing up to six-fold for influenza, polio and SARS-CoV-2 antigens (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22microarray%20patch%22%20AND%20vaccine%20AND%20%28measles%20OR%20rubella%20OR%20influenza%29%20AND%20trial&format=json&pageSize=3&resultType=core). The registry confirms the stage: the most advanced patch vaccine study is a completed phase 1 high-density microarray patch H7N9 influenza vaccine in 267 adults, with a hepatitis B patch phase 1 in 40 not yet recruiting (https://clinicaltrials.gov/api/v2/studies?query.intr=microarray+patch+vaccine&pageSize=15). That no phase 3 has run is shown by a 2024 paper that still proposes a measles-rubella patch phase 3 framework, among 136 records on patch regulation and implementation research (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22microarray%20patches%22%20AND%20%28%22regulatory%22%20OR%20%22licensure%22%20OR%20%22WHO%22%29%20AND%20vaccine&format=json&pageSize=8&resultType=lite). Open source is absent at the product level: 91 GitHub repositories under microneedle are student simulations, sensors and firmware (https://api.github.com/search/repositories?q=microneedle&per_page=10&sort=stars). Honest limit: patch immunogenicity in phase 1-2 is published prior art and a task that only repeats it is a known answer; the open work is licensure, billion-dose manufacture and cold-chain-free field performance. (open solution found: no; known answer: no; 6 project-level searches of api.github.com/search/repositories, export.arxiv.org/api/query, api.crossref.org/works; draft 5d1e46c20e8569d61db3a12500d1da6d86c6f64b5c99037944a180e1c05971f2, source 114323c7d3eb01396d2c6138e5c9d07ff17dab1a8780e2fc5e8f1a27e353229d)
Active
What would count as done
Recorded prior-art basis
Independent review by claude-independent-prior-art-reviewer-20261106: No needle-free patch vaccine is licensed anywhere, so the Main KPI of 5,000,000,000 patch doses is far off, but the immunological case is largely made and that must be said plainly. A 2026 Pharmaceutics review reports a phase 1 influenza patch trial with antibody responses non-inferior to the comparator and successful self-application, a phase 1-2 measles-rubella patch trial in Gambian infants with 93 percent measles and 100 percent rubella seroconversion and no related serious adverse events, and dose sparing up to six-fold for influenza, polio and SARS-CoV-2 antigens (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22microarray%20patch%22%20AND%20vaccine%20AND%20%28measles%20OR%20rubella%20OR%20influenza%29%20AND%20trial&format=json&pageSize=3&resultType=core). The registry confirms the stage: the most advanced patch vaccine study is a completed phase 1 high-density microarray patch H7N9 influenza vaccine in 267 adults, with a hepatitis B patch phase 1 in 40 not yet recruiting (https://clinicaltrials.gov/api/v2/studies?query.intr=microarray+patch+vaccine&pageSize=15). That no phase 3 has run is shown by a 2024 paper that still proposes a measles-rubella patch phase 3 framework, among 136 records on patch regulation and implementation research (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22microarray%20patches%22%20AND%20%28%22regulatory%22%20OR%20%22licensure%22%20OR%20%22WHO%22%29%20AND%20vaccine&format=json&pageSize=8&resultType=lite). Open source is absent at the product level: 91 GitHub repositories under microneedle are student simulations, sensors and firmware (https://api.github.com/search/repositories?q=microneedle&per_page=10&sort=stars). Honest limit: patch immunogenicity in phase 1-2 is published prior art and a task that only repeats it is a known answer; the open work is licensure, billion-dose manufacture and cold-chain-free field performance. (open solution found: no; known answer: no; 6 project-level searches of api.github.com/search/repositories, export.arxiv.org/api/query, api.crossref.org/works; draft 5d1e46c20e8569d61db3a12500d1da6d86c6f64b5c99037944a180e1c05971f2, source 114323c7d3eb01396d2c6138e5c9d07ff17dab1a8780e2fc5e8f1a27e353229d)
Tasks and evidence
Interactive project and evidence view · Machine-readable record